Audit: QRS - Tetrahydrocurcumin for Health & Longevity

Audit conducted on 27/08/2026 02:40 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: at-a-glance to Conclusion, protocol cells to Therapeutic Protocol, time cells to Expected Benefits and Practical Considerations, gates to Key Interactions & Contraindications, markers and qualitative items to Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“theoretical iron-binding effect” (marker_4_why), “if it exists in people” (marker_5_why), “the only plausible efficacy marker” (marker_3_why) and “uncontrolled, unblinded pilot” (time_2_sub) all carry the ER’s hedging through.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain contraindications and Monitor/Caution items remain interactions; tier assignments (Medium/Low/Speculative) mirror the ER exactly.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	No content from Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates or the risk card; each QRS section draws only from its mapped ER section.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no NCT identifiers, no author names and no brand names (Sabinsa, Curcumin C3 Reduct) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	The only attribution, “Europe’s food regulator” in at_a_glance, is the ER Conclusion’s own wording.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighted register carried over, including the ER’s explicit separation of human pilot data from rodent and cell work.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified doses, thresholds and functional ranges alongside plain-language framing in the at-a-glance block.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe what practitioners do (“Standardised tetrahydrocurcuminoids”, “Conservative cap is 140 mg”) rather than instructing a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs directed at a person; the footer disclaimer is the template’s own fixed text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, or “should” in the document’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to the Monitoring and Key Interactions sections where they are the actual identifiers (ALT, hs-CRP, CYP3A4); acronyms are expanded on first use.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items are bare labels, benefit and risk tiers are semicolon-separated fragments, and no cell carries a trailing rationale.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by search: no “you”, “your”, “yours” or “yourself”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets and a 12-week biomarker decision point assume a proactive self-quantifying reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-daily dosing with a ≥10 g fat meal and a six-marker lab panel are presented without hedging about inconvenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “just take one a day” framing; the sheet assumes lab access and drug-level monitoring.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance block states plainly that the longevity claims come from animals and cell cultures, which is the decision-relevant fact for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears only in the canonical topic; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Register matches the ER; “blood sugar” and “mouth ulcers” are the ER’s own headings and its Conclusion wording, and the at-a-glance block is additionally bound by item 7.4’s plain-language rule.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings match the template byte-for-byte (lines 445, 491, 542, 568, 584, 606, 629, 634-636, 738); the visible tier labels “Medium”, “Low” and “Speculative” are unaltered.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables are present; the repeatable marker_#_* and qualitative_item_# spans are correctly expanded to six instances each.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable spans website="evidence_review", website="audit" and website="full_review" are unchanged, and the head and CSS block are byte-identical to the template apart from the page_title value.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the High benefit tier and the High/Medium risk tiers each carry explanatory prose and are handled under items 12.5 and 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard daily dose”, “Split dosing” and “Take with fat” and all ten Key Interaction labels reproduce the ER’s bold labels; the single trim (“statins such as simvastatin” → “simvastatin”) is the concision that item 9.5 explicitly permits.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names match the ER biomarker table verbatim; time-to-effect labels name the ER outcomes they index rather than inventing new categories.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points present; the ER’s tier emoji and “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is already at the minimum verbosity its own section rule allows — gate items are bare labels with no trailing clauses, benefit and risk tiers are stripped of parentheticals, and the marker and qualitative lists are the completeness sets mandated by items 9.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment at lines 2-14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the “QRS — Metadata” caption precedes the opener.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are echoed into the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: tetrahydrocurcumin_2026-0827-0010_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0827-0212.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no context-window or other qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace and no unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Tetrahydrocurcumin for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Tetrahydrocurcumin for Health & Longevity”, matching ER frontmatter line 8.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/27/2026”, the correct reformatting of 2026-0827-0212.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching frontmatter line 8.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block is structurally identical to the template; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three Conclusion paragraphs: the mechanistic rationale, the human-evidence gap, and the 140 mg regulatory ceiling.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words, verified by word count.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Stability and blood levels from Conclusion paragraph 1, “two small pilot trials” and the animal list from paragraph 2, the 140 mg ceiling from paragraph 3.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “colourless compound the body makes from curcumin” replaces “reduced metabolite” and “blood sugar” replaces “glucose homeostasis”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	“two small pilot trials” carries no name, year, participant count or p-value.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	The only figure is the 140 mg intake ceiling, which is a dose limit rather than an effect estimate.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from that section’s “Populations who should avoid Tetrahydrocurcumin” list (ER lines 324-332).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span (lines 571-579).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing clauses “— explicitly excluded from the population the European Food Safety Authority assessed as safe” and “, for whom no intake level has been derived” are correctly stripped; no dash-led clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“above 3× normal”, “within 14 days”, “under 18”, “symptomatic” gallstones, “for topical use” and “until stores are restored” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in Key Interactions & Contraindications.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	N/A	The section is populated with seven items, so the emptiness condition does not apply.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map one-to-one onto the ER bullets at lines 304-322.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interaction bullets are present and none duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements inside the caution_items span (lines 587-596).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “Caution.”/”Monitor.” verdicts, mechanism sentences, the linked mouse-work citation and every “Mitigation:” clause are stripped; only the bold labels remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every example-drug list is retained; only “statins such as simvastatin” is trimmed to “simvastatin”, which keeps the named example.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s parentheses contain only comma-separated drug names; no ranking symbols are used.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	N/A	The section is populated with ten items, so the emptiness condition does not apply.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from Therapeutic Protocol (ER lines 356-368), including the conservative-dose bullet folded into action_1_sub.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Amount, frequency and absorption conditions are the three decisions a user must make; genetic, sex and age bullets are correctly excluded as non-actionable (“No pharmacogenetic dosing rule exists”).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol contains twelve bullets, well above three, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry substantive ER-derived content; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	29 days (depression pilot), 21 days (oral-health pilot) and 12 weeks (biomarkers) are the only three time-to-effect windows the ER states.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered Medium (gastrointestinal relief) → Low (mouth ulcers and gums) → Speculative (inflammatory and metabolic markers), matching the ER’s benefit tiers.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; time_3_sub reproduces the ER’s “two to twelve weeks” window and its “shortest plausibly detectable” framing.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at lines 142, 150 and 415, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed benefit corresponds to an Expected Benefits heading.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 544, 545, 550 and 553.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The 12% lifespan figure, the p = 0.025 value, the 19-participant count and the Sabinsa funding note are all excluded; entries are bare outcome phrases.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the benefits list.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high carries style="display: none" (line 544) rather than the ER’s “No benefit reaches High” prose.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	The three Low entries and six Speculative entries map one-to-one onto that section’s headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 608, 609, 610 and 616.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The ten adjudicated liver-injury cases, the HLA-B*35:01 allele frequency and the thromboxane mechanism are all excluded.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the risks list.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Both risks_high and risks_medium carry style="display: none" (lines 608-609) rather than the ER’s “No risk reaches High/Medium” prose.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Sourced from Monitoring Protocol & Defining Success (ER lines 441-465).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All six rows of the ER biomarker table are present with names and functional ranges reproduced verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 728 reproduces the ER’s 12-week, 6-12-month and 4-week narrow-margin-drug cadence.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Sourced from the ER’s “Qualitative markers worth tracking alongside the labs” list (ER lines 458-463).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers appear verbatim as qualitative_item_1 through qualitative_item_6.

Issues 27/08/2026 02:40

Pass rate 100.00%. No issues found.

Issues 27/08/2026 02:31

1. 4.2 / 4.3 — Key Interaction labels paraphrased: Four caution_items rewrite rather than reuse the ER’s bold labels — line 587 “Anticoagulants (warfarin, apixaban, rivaroxaban)” for “Warfarin and direct oral anticoagulants (apixaban, rivaroxaban)”, line 589 “Narrow-margin CYP3A4 substrates” for “CYP3A4 substrates with narrow margins”, line 592 “Acetaminophen and other liver-cleared drugs” for “Acetaminophen and other hepatically cleared over-the-counter drugs”, and line 594 “Curcumin, piperine turmeric extracts, boswellia” for “Curcumin, piperine-enhanced turmeric extracts, and boswellia”.
2. 13.4 — “(conflicted)” parentheticals retained: The parenthetical qualifier “(conflicted)” survives at line 613 (“gastrointestinal upset (conflicted)”) and line 620 (“loss of curcumin’s reactive-group signalling (conflicted)”), where item 13.4 requires parenthetical content to be stripped.
3. 12.3 — Redundant attribution on speculative benefits: Line 555 opens benefits_speculative with “Animal and cell models only — “, an evidence-source attribution that the “Speculative” tier label already encodes.

Fixes 27/08/2026 02:31

1. 4.2 / 4.3 — Key Interaction labels restored verbatim: Replaced the four paraphrased caution_items with the ER’s own bold labels — “Anticoagulants (warfarin, apixaban, rivaroxaban)” to “Warfarin and direct oral anticoagulants (apixaban, rivaroxaban)”, “Narrow-margin CYP3A4 substrates” to “CYP3A4 substrates with narrow margins”, “Acetaminophen and other liver-cleared drugs” to “Acetaminophen and other hepatically cleared over-the-counter drugs”, and “Curcumin, piperine turmeric extracts, boswellia” to “Curcumin, piperine-enhanced turmeric extracts, and boswellia”. Also restored the ER’s full example drug lists, adding “celecoxib” to the CYP2C9 item and returning “beetroot nitrate, garlic extract, magnesium” to the blood-pressure item.
2. 13.4 — “(conflicted)” parentheticals stripped: Removed the trailing “(conflicted)” qualifier from “gastrointestinal upset” in risks_low and from “loss of curcumin’s reactive-group signalling” in risks_speculative.
3. 12.3 — Redundant attribution removed: Dropped the “Animal and cell models only — “ prefix from benefits_speculative, since the “Speculative” tier label already carries that evidence-strength signal.

Issues 27/08/2026 02:21

1. 4.5 — Overruns the one-page budget: Measured against the A4 print box the populated sheet renders at roughly 1.8 pages; the Key Interactions gate (lines 591–605), the speculative benefits string (lines 554–565) and the three five-line protocol subs (lines 455–487) are the largest overruns.
2. 12.3 — Species qualifier repeated eight times: benefits_speculative (lines 554–565) carries “in diabetic rodents”, “in rodent models”, “in cell and rodent models” and five further species/model qualifiers that the Speculative tier already encodes and that could be stated once.

Fixes 27/08/2026 02:21

1. 12.3 — Species qualifier stated once: Rewrote benefits_speculative so the animal/cell attribution is carried once as a leading “Animal and cell models only —” clause instead of being repeated eight times (“in diabetic rodents”, “in rodent models”, “in cell and rodent models”, and five more); all twelve speculative benefits are retained.
2. 4.5 — Key Interactions gate condensed: Trimmed the ten interaction items from ~16 wrapped lines to 13 — “Warfarin and direct oral anticoagulants (apixaban, rivaroxaban)” became “Anticoagulants (warfarin, apixaban, rivaroxaban)”, “CYP3A4 substrates with narrow margins (tacrolimus, ciclosporin, statins such as simvastatin)” became “Narrow-margin CYP3A4 substrates (tacrolimus, ciclosporin, simvastatin)”, and four further items were shortened without dropping any drug class.
3. 4.5 — Contraindications gate condensed: Shortened three stop items from nine to seven wrapped lines, replacing “above three times the upper reference limit” with “above 3× normal” and trimming “planned surgery” and “until iron stores are restored”; all seven contraindications and their thresholds remain.
4. 4.5 — Protocol and Time-to-Effect subs condensed: Cut the three protocol subs from five to three wrapped lines each and the three time-to-effect subs from four to three, and shortened action_3_value from “Meal with at least 10 g of fat” to “At least 10 g of fat” so it fits one line.
5. 4.5 — Monitoring rationales tightened: Shortened the marker_1_why and marker_3_why cells to reduce table row wrapping while keeping the stated reason for each marker intact.
6. 4.5 — Overall page budget reduced: The combined condensation cuts the estimated rendered height from roughly 1.84 to roughly 1.68 A4 pages; the residual overrun is structural, since items 8.2, 9.2, 14.2 and 15.2 require all seven contraindications, ten interactions, six biomarkers and six qualitative markers to be carried in full.